Online Library
Direct Oral Anticoagulants (DOAC) in oral implant surgery – a metanalysis
EAO Online Library. Tomic J. Oct 9, 2018; 232703; P-SU-113
Josip Tomic
Josip Tomic
Login now to access Regular content available to all registered users.
Discussion Forum (0)
Rate & Comment (0)
Introduction**As oral surgical procedures like implantations and augmentative procedures per se can lead to severe haemorrhagia, in particular patients on anticoagulants require appropriate management.**The “Graz Considerations for Compromised Coagulation“ (GCCC) have been introduced to international field specialists in Vienna, Austria, in 2005 and takes most of invasive dental treatments into account. The recent update of the GCCC has forwarded the optimal peri-procedural haemostatic strategy byMethods**To identify relevant studies a comprehensive and systematic literature research in high-yield journals and the electronic database PubMed was conducted. The broad spectrum of information about perioperative hemostatic strategies was examinded using the following search terms- “oral surgery“, „implant surgery“, “DOAC“ and the agents' proper names. In light of relevant international publications we evaluate our current findings in an ongoing study at our department. **Results**Characteristics of included studies are compared with the pertinent data of our study and listed in tabular form. Seven published papers were included in our critical evaluation. Two cohort studies tested continuation vs. discontinuation of DOAC (Rivaroxaban, Xarelto®) for certain procedures in oral surgery. In one study group no significance for bleeding events of dental implantations was detected in comparison to normal population while another trial showed significance. Three work groups presented their protocols of temporary discontinuation of Dabigatran (Pradaxa®). In strict accordance with their periprocedural strategies the authors observed no significant difference of bleeding events. One working group provides detailed recommendations in a review, but had not assessed them in a clinical trial. An Australian study team recommends both continuation and discontinuation of Dabigatran according to the individual bleeding risk, nevertheless their results may not be represenConclusion****Hematologists advise a minimum time-interval of last dose to intervention. In accordance with our clinical study results we found that continuation of DOAC therapy is advisable for simple implantation without increased risk of local haemorrhage. The DOACs‘ temporary suspension may, however, show fewer bleeding events in procedures such as complex implantation.**As limited data regarding bleeding in implant patients under DOAC therapy is available further studies are needed to determin
Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings